Oxford COVID-vaccine paper highlights lingering unknowns about results
- PMID: 33293710
- DOI: 10.1038/d41586-020-03504-w
Oxford COVID-vaccine paper highlights lingering unknowns about results
Keywords: SARS-CoV-2; Vaccines.
Comment on
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Lancet. 2021. PMID: 33306989 Free PMC article. Clinical Trial.
Similar articles
-
Oxford-AstraZeneca COVID-19 vaccine efficacy.Lancet. 2021 Jan 9;397(10269):72-74. doi: 10.1016/S0140-6736(20)32623-4. Epub 2020 Dec 8. Lancet. 2021. PMID: 33306990 Free PMC article. No abstract available.
-
In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.Ann Intern Med. 2021 Mar;174(3):JC29. doi: 10.7326/ACPJ202103160-029. Epub 2021 Mar 2. Ann Intern Med. 2021. PMID: 33646835
-
Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection.Lancet. 2021 Apr 3;397(10281):1263-1264. doi: 10.1016/S0140-6736(21)00468-2. Epub 2021 Mar 23. Lancet. 2021. PMID: 33765410 Free PMC article. No abstract available.
-
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25. Vaccine. 2020. PMID: 32507409 Free PMC article.
-
Development of vaccines for SARS-CoV-2.F1000Res. 2020 Aug 17;9:F1000 Faculty Rev-991. doi: 10.12688/f1000research.25998.1. eCollection 2020. F1000Res. 2020. PMID: 32850116 Free PMC article. Review.
Cited by
-
Pannexin-1 channel opening is critical for COVID-19 pathogenesis.iScience. 2021 Dec 17;24(12):103478. doi: 10.1016/j.isci.2021.103478. Epub 2021 Nov 19. iScience. 2021. PMID: 34841222 Free PMC article.
-
Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.Viruses. 2021 Mar 5;13(3):418. doi: 10.3390/v13030418. Viruses. 2021. PMID: 33807839 Free PMC article. Review.
-
Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19.Front Mol Biosci. 2021 Apr 15;8:635337. doi: 10.3389/fmolb.2021.635337. eCollection 2021. Front Mol Biosci. 2021. PMID: 33937326 Free PMC article. Review.
-
Does COVID-19 Vaccination Warrant the Classical Principle "ofelein i mi vlaptin"?Medicina (Kaunas). 2021 Mar 9;57(3):253. doi: 10.3390/medicina57030253. Medicina (Kaunas). 2021. PMID: 33803295 Free PMC article. Review.
-
COVID-19: vaccine's progress.Microb Biotechnol. 2021 Jul;14(4):1246-1257. doi: 10.1111/1751-7915.13818. Epub 2021 May 7. Microb Biotechnol. 2021. PMID: 33960659 Free PMC article.
References
-
- Voysey, M. et al. Lancet https://doi.org/10.1016/S0140-6736(20)32661-1 (2020). - DOI - PubMed - PMC
-
- Ramasamy, M. N. et al. Lancet https://doi.org/10.1016/S0140-6736(20)32466-1 (2020). - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous